


60
50
40
30
20
10
0
% apoptotic cells
51.82
43.12
16.76
6.41
1.15
3
1.39
2.96
Hamster Ig
TAB4
Day 0
Day 2
Day 4
Day 6
Days after primary activation


Fig. 1




Ab IP: Antibody used for immunoprecipitation
TA-B4: TA-B4 monoclonal antibody
HNS: Hamster normal serum


Fig. 2


CD4 T







CD8 T






CD19+





Pan-NK+






Fig. 3




Fig. 4



0.6
0.5
0.4
0.3
0.2
0.1
0.0
IL-2 (ng/ml)
Hamster Ig
TAB4
2×10^5
4×10^5
Number of responder cells

Fig. 5



A
Blot with Anti-PSGL-1
kDa
172
111
80
61
IP α-PSGL1 TAB4 NHS
B
IP with TAB4
Depletion:Anti-PSGL-1 ratIgG

Fig. 6



100
80
60
40
20
0
% surviving skin grafts
0
5
10
15
20
25
30
Days after transplantation
Anti-PSGL-1
Control

Fig. 7



25
20
15
10
5
0
% Apoptosis
Anti-PSGL-1+CL
Control Ig+CL
CL
Untreated
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Days After Activation

Fig. 8



100
90
80
70
60
50
40
30
20
10
0
Diabetes Incidence (%)
Hamster Ig
TAB4
18
20
22
24
26
28
Age (weeks)

Fig. 9